IMARC Group, a leading market research company, has recently releases report titled “Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global cholera vaccines market trends, share, size, growth, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Cholera vaccines are biological preparations that contain antigens from the Vibrio cholerae bacterium, which stimulate the immune system of the body to recognize and fight against the bacteria. They are usually administered orally, making them easier to distribute and administer as compared to injectable vaccines. They are generally safe with mild side effects and aid in reducing the severity and duration of the disease, leading to lower mortality and morbidity rates. They help minimize the overuse of antibiotics in treating cholera cases. They are widely used in mass vaccination campaigns, especially in areas with poor sanitation and high risk of cholera outbreaks. Besides this, they are also utilized in emergencies, such as natural disasters or humanitarian crises around the world. Moreover, they are recommended for specific high-risk groups, such as healthcare workers.

The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032. 

Request Sample Copy of This Report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample

What are the growth prospects and trends in the cholera vaccines industry?

The increasing prevalence of cholera, especially in regions with poor sanitation and limited access to clean water, is influencing the market positively. Moreover, ongoing research to develop more effective cholera vaccines, including work on single-dose and orally administered vaccines, is making vaccination programs more efficient and cost-effective. Besides this, rising partnerships between vaccine manufacturers, governments, non-government organizations (NGOs), and international health bodies are offering a favorable market outlook. Such collaborations ensure a coordinated approach to addressing cholera risks.

Furthermore, the governing authorities of several countries are implementing regulations mandating the inclusion of cholera vaccination in public health programs, which is driving the demand for cholera vaccines. In addition, rapid enhancements in the vaccine supply chain, particularly in cold chain logistics, are making it possible to deliver vaccines to remote and resource-limited settings, expanding the market reach. Besides this, the growing involvement of private sector entities in vaccine production and distribution is leading to increasing investments and innovation in the market. Furthermore, several international health organizations like WHO are increasingly focusing on cholera, providing funding, resources, and strategic planning for vaccination programs, which is stimulating the market growth. These initiatives are driving the demand and improving access to cholera vaccines in underserved regions. Moreover, the rising awareness among the masses about cholera prevention and vaccination benefits is strengthening the growth of the market.

Along with this, the expansion of travel medicine across the globe is creating a positive outlook for the market. Cholera vaccines are increasingly recommended for travelers traveling to endemic regions, expanding the consumer base. In addition, advancements in genomic and epidemiological research are providing deeper insights into the transmission dynamics and evolution of the Vibrio cholerae bacterium. This, in turn, is facilitating the development of targeted vaccines and aids in predicting and preparing for potential outbreaks, which is strengthening the market growth. Furthermore, improvements in healthcare facilities, including better storage capabilities for vaccines and more skilled healthcare workers, are enabling more effective distribution and administration of cholera vaccines.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Vaccine Type:

  • Whole Cell V. Cholerae O1 with Recombinant B-Subunit
  • Killed Oral O1 and O139

Breakup by Product:

  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol and Euvichol-Plus
  • Others

Breakup by End User:

  • Hospitals and Clinics
  • Research and Academic Laboratories
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

  • Astellas Pharma Inc.
  • Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
  • Emergent BioSolutions Inc.
  • Eubiologics Co. Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • PharmaChoice Canada Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163